Bookmark Us
All Food, Diet and Health News 
 Misc. News
 Must-Read News
 Letter to Editor
 Featured Products
 Recalls & Alerts
 Consumer Affair
 Non-food Things
 Health Tips
 Interesting Sites
 Diet & Health
 Heart & Blood
 Body Weight
 Children & Women
 General Health
 Food & Health
 Food Chemicals
 Biological Agents
 Cooking & Packing
 Agri. & Environ.
 Laws & Politics
 General Health
 Drug News
 Mental Health
 Infectious Disease
 Other News
 Food Consumer
 FC News & Others

Search Foodconsumer & Others

Add to Google
Add to My Yahoo
Newsfeed news feed
Su bmit news[release]

More than 100 credit cards available at from, you can pick more than 100 credit cards

General Health : Government Last Updated: Apr 20, 2011 - 9:38:09 AM

Got urination problem? FDA got a new drug for you
By Sue Mueller
Nov 2, 2008 - 8:44:04 AM

E.mail t.his a.rticle
 P.rinter f.riendly p.age
Get n.ewsletter
Vita.min C lowers blo.od pre.ssure

Saturday November 1, 2008 ( – The U.S. Food and Drug Administration announced on Friday that it had approved a new treatment called Toviaz (fesoterodine fumarate) to help patients suffering from overactive bladder or OAB.


Overactive bladder (OAB) is a urological condition that causes abnormal urination with symptoms including increased urinary frequency, urge to urinate and leakage of urine.


Toviaz manufactured by Schwarz Pharma of Zwickau, Germany and distributed by Pfizer Inc. of New York, N.Y. works by relaxing the smooth muscle tissue of the bladder, according to the FDA.


Common treatments for OAB include diet modification, bladder retraining, antimuscarinic drugs and various devices, wikipedia says.   Intravesical botulinum toxin A is also used in some cases although the FDA did not formally approve the therapy.


"This new drug will provide an additional treatment option to help them manage problems with an overactive bladder." said George Benson, M.D., deputy director, Division of Reproductive and Urologic Products at the FDA’s Center for Drug Evaluation and Research.


Toviaz will be available by prescription only for adults, sold in forms of tablets with 4 mg or 8 mg dosages and administrated once a day, the FDA said.


The drug was approved based on data on its safety and efficacy obtained from two 12-week trials of a total more than 1500 patients of whom the majority was female and aged 58 years on average.


The FDA said in its announcement that in each of those two studies, Toviaz showed statistically significant and clinically meaningful improvement in decreasing the number of times patients needed to urinate per day and also the number of urine leaking episodes each day.


Like all medications, Toviaz causes side effects including dry mouth and constipation, less commonly dry eyes and trouble emptying the bladder.


The FDA warned that this medication is not recommended in doses above 4 mg for patients with severe reduction in kidney function, those patients taking certain medications and those who suffer from decreased gastrointestinal motility, such as those with severe constipation.

© 2004-2008 by unless otherwise specified

Top of Page


Search Consumer-friendly Health Sites

We have moved to Food Consumer . Org

disclaimer | advertising | jobs | privacy | about us | newsletter | Submit news/articles
link partners: | Buy Viagra | |
Buy a home | Auto Insurance | Mortgage refinancing | | Take Your Blog to a Higher Level
© Copyright 2004 - 2008 All rights reserved

Disclaimer: What's published on this website should be considered opinions of respective writers only and which has no political agenda nor commercial ambition may or may not endorse any opinion of any writer. No accuracy is guaranteed although writers are doing their best to provide accurate information only. The information on this website should not be construed as medical advice and should not be used to replace professional services provided by qualified or licensed health care workers. The site serves only as a platform for writers and readers to share knowledge, experience, and information from the scientific community, organizations, government agencies and individuals. encourages readers who have had medical conditions to consult with licensed health care providers - conventional and or alternative medical practitioners.